Malta - Inggris - Medicines Authority

accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - paricalcitol - solution for injection - paricalcitol 5 µg/ml - calcium homeostasis

Malta - Inggris - Medicines Authority

accord healthcare limited - paricalcitol - solution for injection - paricalcitol 2 µg/ml - calcium homeostasis

Malta - Inggris - Medicines Authority

accord healthcare limited - paricalcitol - solution for injection - paricalcitol 5 µg/ml - calcium homeostasis

Malta - Inggris - Medicines Authority

accord healthcare limited - paricalcitol - solution for injection - paricalcitol 5 µg/ml - calcium homeostasis

Amerika Serikat - Inggris - NLM (National Library of Medicine)

bryant ranch prepack - paricalcitol (unii: 6702d36og5) (paricalcitol - unii:6702d36og5) - paricalcitol capsules are indicated in adults for the prevention and treatment of secondary hyperparathyroidism associated with chronic kidney disease (ckd) stages 3 and 4. pediatric use information for patients 10 to 16 years of age is approved for abbvie inc.’s zemplar (paricalcitol) capsules. however, due to abbvie inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. paricalcitol capsules are indicated in adults for the prevention and treatment of secondary hyperparathyroidism associated with ckd stage 5 in patients on hemodialysis (hd) or peritoneal dialysis (pd). pediatric use information for patients 10 to 16 years of age is approved for abbvie inc.’s zemplar (paricalcitol) capsules. however, due to abbvie inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. paricalcitol capsules should not be given to patients with evidence of - hypercalcemia or hypercalcemia or - vitamin d toxicity [see warnings and

Amerika Serikat - Inggris - NLM (National Library of Medicine)

bryant ranch prepack - paricalcitol (unii: 6702d36og5) (paricalcitol - unii:6702d36og5) - paricalcitol capsules are indicated in adults for the prevention and treatment of secondary hyperparathyroidism associated with chronic kidney disease (ckd) stages 3 and 4. pediatric use information for patients 10 to 16 years of age is approved for abbvie inc.’s zemplar (paricalcitol) capsules. however, due to abbvie inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. paricalcitol capsules are indicated in adults for the prevention and treatment of secondary hyperparathyroidism associated with ckd stage 5 in patients on hemodialysis (hd) or peritoneal dialysis (pd). pediatric use information for patients 10 to 16 years of age is approved for abbvie inc.’s zemplar (paricalcitol) capsules. however, due to abbvie inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. paricalcitol capsules should not be given to patients with evidence of - hypercalcemia or hypercalcemia or - vitamin d toxicity [see warnings and

Israel - Inggris - Ministry of Health

abbvie biopharmaceuticals ltd, israel - paricalcitol - solution for injection - paricalcitol 5 mcg/ml - paricalcitol - paricalcitol - paricalcitol is indicated for the prevention and treatment of secondary hyperparathyrodism associated with chronic renal failure.

Amerika Serikat - Inggris - NLM (National Library of Medicine)

cardinal health - paricalcitol (unii: 6702d36og5) (paricalcitol - unii:6702d36og5) - paricalcitol 1 ug

Amerika Serikat - Inggris - NLM (National Library of Medicine)

abbvie inc. - paricalcitol (unii: 6702d36og5) (paricalcitol - unii:6702d36og5) - paricalcitol 2 ug in 1 ml - zemplar is indicated for the prevention and treatment of secondary hyperparathyroidism in patients 5 years of age and older with chronic kidney disease (ckd) on dialysis. zemplar is contraindicated in patients with: - hypercalcemia [see warnings and precautions ( 5.1 )] - vitamin d toxicity [see warnings and precautions ( 5.1 )] - known hypersensitivity to paricalcitol or any of the inactive ingredients in zemplar. hypersensitivity adverse reactions have been reported [e.g., angioedema (including laryngeal edema) and urticaria] [see adverse reactions ( 6.2 )] . risk summary limited data with zemplar in pregnant women are insufficient to inform a drug-associated risk for major birth defects and miscarriage. there are risks to the mother and fetus associated with chronic kidney disease in pregnancy (see clinical considerations ) . in animal reproduction studies, slightly increased embryofetal loss was observed in pregnant rats and rabbits administered paricalcitol intravenously during the period of organogenes

Israel - Inggris - Ministry of Health

abbvie biopharmaceuticals ltd, israel - paricalcitol - capsules soft - paricalcitol 1 mcg - paricalcitol - zemplar is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal insufficiency (chronic kidney disease stage 3 and 4 ) patients and chronic renal failure (chronic kidney disease stage 5) patients on haemodialysis or peritoneal dialysis.